Država: Nizozemska
Jezik: nizozemski
Izvor: CBG-MEB (College ter Beoordeling van Geneesmiddelen)
DROSPIRENON 3 mg/stuk ; ETHINYLESTRADIOL 0,02 mg/stuk
Egis Pharmaceuticals Plc Kereszturi ut 30-38 1106 BOEDAPEST (HONGARIJE)
G03AA12
DROSPIRENON 3 mg/stuk ; ETHINYLESTRADIOL 0,02 mg/stuk
Filmomhulde tablet
CROSCARMELLOSE NATRIUM (E 468) ; IJZEROXIDE GEEL (E 172) ; IJZEROXIDE ROOD (E 172) ; IJZEROXIDE ZWART (E 172) ; LACTOSE 0-WATER ; LACTOSE 1-WATER ; MACROGOL 3350 ; MAGNESIUMSTEARAAT (E 470b) ; MAÏSZETMEEL, GEPREGELATINEERD ; POLYSORBAAT 80 (E 433) ; POLYVINYLALCOHOL, GEDEELTELIJK GEHYDROLYSEERD (E1203) ; POVIDON K 30 (E 1201) ; TALK (E 553 B) ; TITAANDIOXIDE (E 171), CROSCARMELLOSE NATRIUM (E 468) ; IJZEROXIDE GEEL (E 172) ; IJZEROXIDE ROOD (E 172) ; IJZEROXIDE ZWART (E 172) ; LACTOSE 0-WATER ; LACTOSE 1-WATER ; MACROGOL 3350 ; MAGNESIUMSTEARAAT (E 470b) ; MAÏSZETMEEL, GEPREGELATINEERD ; POLYSORBAAT 80 (E 433) ; POLYVINYLALCOHOL, GEDEELTELIJK GEHYDROLYSEERD (E1203) ; POVIDON K 30 (E 1201) ; TALK (E 553 B) ; TITAANDIOXIDE (E 171),
Oraal gebruik
Drospirenone And Ethinylestradiol
Hulpstoffen: CROSCARMELLOSE NATRIUM (E 468); IJZEROXIDE GEEL (E 172); IJZEROXIDE ROOD (E 172); IJZEROXIDE ZWART (E 172); LACTOSE 0-WATER; LACTOSE 1-WATER; MACROGOL 3350; MAGNESIUMSTEARAAT (E 470b); MAÏSZETMEEL, GEPREGELATINEERD; POLYSORBAAT 80 (E 433); POLYVINYLALCOHOL, GEDEELTELIJK GEHYDROLYSEERD (E1203); POVIDON K 30 (E 1201); TALK (E 553 B); TITAANDIOXIDE (E 171);
2014-12-30
1 PACKAGE LEAFLET: INFORMATION FOR THE USER FEMILUX 3 MG/0,02 MG FILMOMHULDE TABLETTEN DROSPIRENONE AND ETHINYLESTRADIOL READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor, pharmacist or nurse. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Femilux is and what it is used for 2. What you need to know before you take Femilux 3. How to take Femilux 4. Possible side effects 5. How to store Femilux 6. Contents of the pack and other information IMPORTANT THINGS TO KNOW ABOUT COMBINED HORMONAL CONTRACEPTIVES (CHCS): · They are one of the most reliable reversible methods of contraception if used correctly · They slightly increase the risk of having a blood clot in the veins and arteries, especially in the first year or when restarting a combined hormonal contraceptive following a break of 4 or more weeks · Please be alert and see your doctor if you think you may have symptoms of a blood clot (see section 2 “Blood clots”) 1. WHAT FEMILUX IS AND WHAT IT IS USED FOR • This medicine is a contraceptive pill and is used to prevent pregnancy. • Each of the 24 pink tablets contain a small amount of two different female hormones, namely drospirenone and ethinylestradiol. • The 4 white tablets contain no active substances and are also called placebo tablets. • Contraceptive pills that contain two hormones are called “combination” pills. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE FEMILUX GENERAL NOTES Before you start using Femilux you should read the information on blood clots in section 2. It is particularly important to read the symptoms of a b Pročitajte cijeli dokument
1/21 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Femilux 3 mg/0,02 mg filmomhulde tabletten 2. QUALITATIVE AND QUANTITATIVE COMPOSITION _24 pink film-coated tablets (active tablets): _ Each film-coated tablet contains 3 mg drospirenone and 0.02 mg ethinylestradiol. Excipient with known effect Lactose monohydrate 44 mg _4 white placebo (inactive) film-coated tablets: _ The tablet does not contain active substances Excipient with known effect Lactose anhydrous 89.5 mg For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet. The active tablet is pink, round film-coated tablet of 5.7 mm diameter. The placebo tablet is white, round film-coated tablet of 5.7 mm diameter. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Oral contraception. The decision to prescribe Femilux should take into consideration the individual woman’s current risk factors, particularly those for venous thromboembolism (VTE), and how the risk of VTE with Femilux compares with other combined hormonal contraceptives (see sections 4.3 and 4.4). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology HOW TO TAKE FEMILUX 2/21 The tablets must be taken every day at about the same time, if necessary with a little liquid, in the order shown on the blister strip. Tablet taking is continuous. One tablet is to be taken daily for 28 consecutive days. Each subsequent strip is started the day after the last tablet of the previous strip. Withdrawal bleeding usually starts on day 2-3 after starting the placebo tablets (last row) and may not have finished before the next strip is started. HOW TO START FEMILUX • No preceding hormonal contraceptive use (in the past month) Tablet-taking has to start on day 1 of the woman’s natural cycle (i.e. on the first day of her menstrual bleeding). • Changing from a combined hormonal contraceptive (combined oral contraceptive (COC), vaginal ring or transdermal patch) The woman should start with Femilux preferably on the day after the last active tablet (the last Pročitajte cijeli dokument